Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma

Her Shyong Shiah, Yee Chao, Li Tzong Chen, Tzy Jyun Yao, Jin Ding Huang, Jang Yang Chang, Pei Jer Chen, Tsai Rong Chuang, Yung Hsin Chin, Jacqueline Whang-Peng, Tsang Wu Liu

研究成果: 雜誌貢獻文章同行評審

11 引文 斯高帕斯(Scopus)


Purpose: To evaluate the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and pharmacokinetics of thalidomide in patients with advanced hepatocellular carcinoma (HCC). Methods: Patients with advanced HCC who were not feasible for definitive local therapy were eligible. Patients were enrolled in a cohort of three to receive thalidomide twice daily for 1 week to determine the MTD. Intra-patient dose escalation was permitted. Pharmacokinetic studies were performed at the first dose level and repeated at the second dose level of each patient. Results: Fifteen patients were accrued at four dose levels with the starting dose range 100-400 mg/day. Two patients at 400 mg/day experienced DLT (grade 3 angioedema and dyspnea, respectively). The MTD of twice-daily schedule was determined as 300 mg/day. The mean steady-state maximal blood concentration and mean steady-state area under the curve had a trend toward positive correlation, but non-linear proportionate, to the daily dose of thalidomide. Pharmacokinetic parameters are comparable for patients of Child-Pugh's A and B. Apparent mild, transient drug-induced transaminitis was early onset, self-limited, which occurred in 30.7% of patients. Serum hepatitis B or C viral titers was largely not affected. Conclusion: The absorption and elimination of thalidomide are not significantly different in HCC patients with compensated or decompensated hepatic dysfunction.
頁(從 - 到)654-664
期刊Cancer Chemotherapy and Pharmacology
出版狀態已發佈 - 1月 1 2006

ASJC Scopus subject areas

  • 腫瘤科
  • 毒理學
  • 藥理
  • 癌症研究
  • 藥學(醫學)


深入研究「Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma」主題。共同形成了獨特的指紋。